UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Proceedings of the National Academy of Sciences - PNAS, 2013-03, Vol.110 (10), p.3991-3996

2013

Volltextzugriff (PDF)

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations

Hepatology (Baltimore, Md.), 2011-12, Vol.54 (6), p.1924-1935

2011

Volltextzugriff (PDF)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

Clinical infectious diseases, 2020-12, Vol.71 (12), p.3110-3117

2020

Volltextzugriff (PDF)

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Nature (London), 2010-05, Vol.465 (7294), p.96-100

2010

Volltextzugriff (PDF)

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Hepatology (Baltimore, Md.), 2011-12, Vol.54 (6), p.1956-1965

2011

Volltextzugriff (PDF)

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

The Journal of infectious diseases, 2012-10, Vol.206 (7), p.1002-1011

2012

Volltextzugriff (PDF)

Prevalence of Darunavir Resistance in the United States from 2010 to 2017

AIDS research and human retroviruses, 2018-12, Vol.34 (12), p.1036-1043

2018

Volltextzugriff (PDF)

Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

Journal of pharmaceutical sciences, 2013-06, Vol.102 (6), p.1742-1751

2013

Volltextzugriff (PDF)

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017

AIDS research and human retroviruses, 2019-08, Vol.35 (8), p.698-709

2019

Volltextzugriff (PDF)

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Journal of virology, 2006-07, Vol.80 (13), p.6441-6457

2006

Volltextzugriff (PDF)

Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis

Clinical infectious diseases, 2000-04, Vol.30 (4), p.633-638

2000

Volltextzugriff (PDF)

Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring

Clinical infectious diseases, 2006-04, Vol.42 (8), p.1189-1196

2006

Volltextzugriff (PDF)

Genotypic Analysis of HIV-1 Drug Resistance at the Limit of Detection: Virus Production without Evolution in Treated Adults with Undetectable HIV Loads

The Journal of infectious diseases, 2004-04, Vol.189 (8), p.1452-1465

2004

Volltextzugriff (PDF)

G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo

Journal of Virology, 2005-02, Vol.79 (3), p.1975-1980

2005

Volltextzugriff (PDF)

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

Hepatology (Baltimore, Md.), 2012-06, Vol.55 (6), p.1692-1699

2012

Volltextzugriff (PDF)

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART

JAMA : the journal of the American Medical Association, 2005-02, Vol.293 (7), p.817

2005

Volltextzugriff (PDF)

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.722-728

2011

Volltextzugriff (PDF)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

AIDS research and therapy, 2019-08, Vol.16 (1), p.23-23, Article 23

2019

Volltextzugriff (PDF)

Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen

Clinical pharmacology in drug development, 2019-05, Vol.8 (4), p.541-548

2019

Volltextzugriff (PDF)

HIV-1 viral load blips are of limited clinical significance

Journal of antimicrobial chemotherapy, 2006-05, Vol.57 (5), p.803-805

2006

Volltextzugriff (PDF)

Genotypic Resistance in HIV-1—Infected Patients with Persistently Detectable Low-Level Viremia while Receiving Highly Active Antiretroviral Therapy

Clinical infectious diseases, 2004-10, Vol.39 (7), p.1030-1037

2004

Volltextzugriff (PDF)

Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin Use

Clinical infectious diseases, 2004-03, Vol.38 (5), p.731-736

2004

Volltextzugriff (PDF)

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Drugs in R&D, 2018-09, Vol.18 (3), p.199-210

2018

Volltextzugriff (PDF)

Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial

Reviews on recent clinical trials, 2017-01, Vol.12 (3), p.174

2017

Volltextzugriff (PDF)

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir

Drugs in R&D, 2018-09, Vol.18 (3), p.249-250

2018

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(108)

Sprache

Englisch
(108)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(64)
Humans
(53)
Infectious Diseases
(32)
Male
(31)
Biological And Medical Sciences
(28)
Female
(26)
Medical Sciences
(25)
Adult
(23)
Microbiology
(21)
Middle Aged
(21)
Hiv Infections - Drug Therapy
(17)
Immunology
(17)
Hiv
(15)
Pharmacology & Pharmacy
(15)
Human Viral Diseases
(13)
Viral Diseases
(13)
Human Immunodeficiency Virus
(12)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(12)
Aged
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

Prevalence of Darunavir Resistance in the United States from 2010 to 2017

Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis

Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring

Genotypic Analysis of HIV-1 Drug Resistance at the Limit of Detection: Virus Production without Evolution in Treated Adults with Undetectable HIV Loads

G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen

HIV-1 viral load blips are of limited clinical significance

Genotypic Resistance in HIV-1—Infected Patients with Persistently Detectable Low-Level Viremia while Receiving Highly Active Antiretroviral Therapy

Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin Use

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir

Suchergebnisse filtern